The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

Researchers say they've discovered an already approved migraine drug that can stop symptoms hours before a severe headache ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

American health officials have recommended temporarily halting the use of Ixchiq (chikungunya virus vaccine, live) in people ...